50591-23-6

Upstream product

• 10394-42-0 6-methoxy-1-methylbenzimidazole 
• 53484-16-5 6-bromo-1-methyl-1H-benzo[d]imidazole 
• 69397-93-9 N-methyl-5-methoxy-2-nitroaniline 
• 394-41-2 3-fluoro-4-nitrophenol 
• 64-18-6 formic acid 
• 14703-79-8 3-(methylamino)-4-nitrophenol 
• 109643-21-2 toluene-4-sulfonic acid-(5-methoxy-N-methyl-2-nitro-anilide) 
• 109508-87-4 N-(5-methoxy-2-nitrophenyl)-p-toluenesulfonamide 

Relevant academic research and scientific papers

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS

The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.